UTHR - Earnings call 3 2023 | United Therapeutics Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2023 Earnings Webcast. My name is Rafael and I will be your conference operator today. [Operator Instructions] Please note, this call is being recorded.

I will now turn the webcast over to Dewey Steadman, Head of Investor Relations, United Therapeutics. ahead. go Please

Dewey Steadman

are Product and our welcome Rafael, Dr. XXXX everyone. my me It's Webcast. and our Vice our Thank our Executive Chief to President Executive President good the Edgemond, to Officer; today accompanying -- you me Quarter Martine of Operating and Leigh and United Executive Officer pleasure Rothblatt, Accompanying Chairperson you, Development Technical today morning, Dr. Officer; Therapeutics Earnings Chief Benkowitz, Financial of Treasurer; and Peterson, Vice President our Michael James Operations; and Chief Xenotransplantation. Pat Poisson, Third

materially. today future statements events. Remarks uncertainties representing regarding involve statements or differ risks and beliefs actual forward-looking include These cause that our will may expectations to results

XX-K update these statements. Our contain and including XX-Q, risks these SEC additional forward-looking to We on filings, assume obligation uncertainties. forms and no information latest

Also that products. solely today's or intended the with the suggest trials decision-making discuss are website. and for developments respect to investigational products and Full remarks information for clinical products are of not for serve These progress medical unapproved or uses. prescribing to and results remarks or educate investors may on available basis our are to these are our other to any safe intended as effective any

And early meetings Note one-on-one Healthcare Conference will that Rothblatt and one-on-one UBS the fireside January. the JPMorgan at Pat fireside November Martine and Poisson a and session XXXX X. I Conference will at a be presenting in participate chat in meetings chat Biopharma in on

business of of our to Dr. results United over Therapeutics. for third and turn overview financial the an I'll call Now Martine? quarter XXXX activities the Rothblatt

Martine Rothblatt

Thank Dewey. you,

to as an congratulate like third we I'd quarter. had team off, First amazing our

of revenue second quarter net profile quarter with quarterly for double-digit along to with per efficiency that, ever, ever. At growth quarterly report our biotech. resulted I'm the growth, highest the one in as to On share uniquely quarter unique third in the our incomes in operational XXXX. in United top compared revenue a and For Therapeutics, that's our of highest of thrilled of row, third positioned waves we're earnings a X

Our first or by interstitial business wave commercial in our led with Tyvaso through associated will lung existing pulmonary hypertension growth PH-ILD. of come disease

to continue growth business post with a whole. quarterly treprostinil current as on solid and record therapy We patients our in products revenue for

Our in leadership detail Tyvaso commercial will Michael growth go pulmonary prescribed and hypertension, call. U.S. business our and led the in in continued to the PAH, prostacyclin combining on to into nebulized products or later arterial in has become most Tyvaso PH-ILD DPI therapy this

rate. least in growth revenue We doubling our believe annual term $X implying we run this a revenue growth and annual double-digit will expect and compound rate at by a near XXXX continue mid-decade, the from billion

and near-term led provide Our again in second X wave Ralinepag approved, will program of I end from come decade. double of our the $X products, to the TETON by growth These shortly. PAH. TETON pulmonary on the Ralinepag pipeline could program in will our updates revenue by and the lead billion to if fibrosis

these of impacts potential and we and entrants, Act. good of both the meeting course, new Reduction approvals, growth aspirations. second But of our revenue our regulatory to competitive waves about first outcomes, trial the for subject prospects Of Inflation clinical are feel

disease. of come a will and Our through technologies use to development, experiencing end-stage organs manufacture to heart the solution and and manufactured widespread kidney, liver third lung, organ wave of sustainable growth provide patients

TETON PPF, now or Group an TETON X X PAH. idiopathic for and now oral pipeline fibrosis, therapy X we near-term progressive Moving TETON of and TETON second consists registration key X wave to for for have pulmonary pulmonary fibrosis, pulmonary our and programs registration TETON X for of growth, underway: studies, fibrosis. IPF, and Ralinepag,

IPF aiming lung this with States, And TETON just decline. XXX only believe approved represents we X distinct X a Both patient patients studies patient for both the U.S., therapies time, slow We that end believe which we in patients. United are a of XXX,XXX enrollment function at to enrolling XXXX. Likewise, by with the up in and opportunity full opportunity the each in PPF IPF. represents from TETON X XX,XXX is are

decline PPF X the these patients. function in approved therapies like for only approved slows of One IPF, and, also fragile IPF the is it of in FDA lung

As TETON has PPF study its we reported the week, this earlier dosed first patient.

probability IPF subset expect of on Committee data Tyvaso function an high of of believe a Tyvaso study had along the there TETON the a success on these therapies this recent in routine of the nebulized enroll and unanimously improvement safety X XXX is that pulmonary market, showed trial Unlike subset patients. We studies a encouraged from Safety the in TETON review without the of safety studies. with patients. Data Monitoring X INCREASE hospitalization. X PH-ILD XXX patients continuation X lung in relatively from data endpoint recommended trials The in TETON of based also IPF completed the both review patients by and We by unblinded hypertension. to committee patients IPF in We're an a of nebulized of

prostacyclin as PAH. for other as therapies patients. currently dosing, for other receptor it available against of prostacyclin is Group this We once-daily X position targeting potent and as we once-daily outcome enroll therapy And release patients. are developing PAH PAH and in time, believe next-generation study continues receptor a Ralinepag's sustained profile at study oral well the agonist and could titrate-ability of in advanced agonists favorably selective a we XXXX. Our the oral completion are Ralinepag to Ralinepag it

And coverage provides with in XX% epoprostenol. intravenous receptor improvement II to demonstrated other Phase improvement pulmonary observed close studies. the XX-hour more potency of vascular agonists Ralinepag XXx Ralinepag to in X.X market. prostacyclin the on the the in That's oral than resistance

block studies sustained also Phase II Ralinepag showed Long-term open-label in of improvement X-minute distance.

Data modification, after the for evaluating that announce in met the of and advanced to study. from Monitoring without for trial unanimously continuation study Committee enrolled fourth the outcome unblinded pleased Safety data the recommended the the XXX patients last month time are We

XXX in pace We to accruing worsening are of X,XXX on clinical patients depending the the events. targeting study

to Moving programs. our organ

using technologies We investigational developing organs. with different been several different approaches have

The EVLP. first products hearts perfusion our of ex-vivo Xeno is lung with service, transplantation over which also EVLP, to that saved or undergone lives developing kidneys. consisting XXX and led have has lungs We're

and printing been medicine working lungs XD kidneys. manufactured technologies we've Finally, on and develop to regenerative

is recently implant that want cells, the At based simple held of kidney core purification, engineered Iviva United durable always privately out need Medical Massachusetts. Iviva's an multiple Iviva's kidney shots Therapeutics, goal. we we native end, technology kidney To acquired that immunosuppression. on a to with implantable, patient's architecture eliminating kidney. a with mimics native achieve the seeded blood elements much own for like is Woburn,

an organ of key liver traded provide platform focused failure. temporary week, MiroMatrix replace company kidney, then X Medical, existing intended organ agreement with to waiting this intended implanted ending ex announced that organs liver. that recellularized MiroMatrix of or decellularized is nontransplantable organs some to the a earlier porcine consists from for the and a transplantation. liver acute cells manufactured we acquire pipeline. outside vivo and list Matrix constructs fully functionality that are external the dialysis organ MiroliverELAP, organs. These immunosuppression on transplantation standard to techniques Mirokidney, broaden programs human would which has body implantable fully using organ organ regimens. Miro Miroliver, an of manufacturing are for publicly human Also, utilizes donor our and a derived

to Xenotransplantation. Moving

with underway at We FDA forward. continue preclinical we the on in pivotal the to with work clinical We're studies what of FDA. the path call request a baboons

xeno-organs. In early collecting FDA occur data, discuss for meet the Specifically, we transplant clinical program, or we're After in with to XX-gene stage preclinical wrapping for xenokidney construction preclinical IND XXXX. the studies, the our human Pathogen clinical studies parallel with of Free DPF, Designated last the pivotal our up expect Virginia. for the our and facility, we'll protocol to XX-gene in

XXXX the balance in of in clinical in to through both to begin for XXXX receiving grow expect preparation population the humans pigs for xenohearts. the and facility We its facility xenokidneys early for and studies

testing lungs towards forward by to medicine New our large group these regenerative programs, xenotransplantation our using our We detail Carolina-based mammal North our our And printed technologies look XD sharing lungs manufacturing that, organ Behind autologous on Systems. manufactured behind Hampshire-based by progress team. XD now they from in more as clinical partner, our studies. programs

such I'm at thrilled United that great in we're Therapeutics. a position

the and ahead, largest record critical posting of that, And revenues have employees address we succeed. one of with a that growth to all pipeline our have all shareholders needs a therapies patients, commercial of results long-term double while our business could medical of employers helping strong unmet on the decade. the top and again end by novel a the plan solid continued of We

call President, goal a our Mike? over Michael our I'll give who and now $X to near-term turn Benkowitz, commercial overview annual by our mid-decade. for billion an run of of progress performance rate revenue the will

Michael Benkowitz

and everyone. Martine, morning, Thanks, good

get Orenitram, ever reflects today, to of patient transition quarter, and from which able the our we titration novo. increases noted, the Tyvaso We our publication third allowing for commence $XXX from of Martine highest third peer-reviewed the saw side and efforts de As million, each rapid higher we growth to field-based we on by on study, franchise, reported at XX% the quarter quarter Remodulin In less the meaningful dose. also revenue of XXXX. up respect the year. Orenitram education teams of both protocol This Unituxin. With up with average and to to Orenitram Orenitram, starting million the based was growth revenue following doses during X Remodulin, and to prior our X% saw growth $XX of effects are Orenitram than quarter, quicker patients to is which EXPEDITE manuscripts,

the million of Patients from as Remodulin the increase from U.S. XX% an from revenue in sales third growth international year, Remodulin in same both XX% to prescribed period at Remodulin the who quarter year. parenteral period as make now #X up U.S. more $XXX U.S. use last was well under patient continues the be of reflecting last to year. Remunity in up just our XXXX the for of same Pump the XX% compared subcutaneous PAH therapy than patients last

a modest million, from prior the sales was and year We Moving up inventory our build $XX U.S. revenue XX% U.S. in includes was increase This quarter. distributor. of an driven at by to which saw growth Unituxin.

$XXX and among report to as patient Tyvaso. Tyvaso quarter the nebulized from now for therapy was of proud number the and This for business on year and well Finally, highest of uptake prescribed revenue expansion therapy. ever. the the Tyvaso patients that approved saw the treatment quarter driven the PH-ILD. performance the reflects revenue Tyvaso is of This highest was and remains Tyvaso DPI was in new up which principally as physicians We PH-ILD We the Tyvaso Tyvaso XX% and by DPI combined referrals rapid prostacyclin only market. million #X prior saw combined, for continued quarter. patients, U.S. during into the starts I'm the growth

and MannKind come that year, partner Regarding expand Tyvaso of of Tyvaso phase equipment forward. went online ample helped with of supply positioned has us the further DPI process These meaningfully will the our coupled to new to moving inventory, provide enhancements, that DPI supply have first Tyvaso well online June next at DPI. a improvements expansion in

drive approved the before. to where only as Tyvaso now I growth working remains in We're mentioned PH-ILD, product,

recently, regional last nurse focus these driving our liaisons, to we're prescribers increasing to reimbursement We medical more specialists our With representatives size able specialists been sales expansion, within prescribers. the adding team. on depth teams field-based both reach this over have XX the more science importantly, of and, months, and, and

And we've already progress. made great

than about these true and of more in the the mentioned a more earnings we've prescriber, last prescribers. that prescribers in growth at Tyvaso total per since maintain I depth, as call, number patients also are ILD approval rather X those back into about physicians Peeling these coming On doubled ILD XXXX, those on having little the clinics. about now our bit, defined that of of the XX% PH-ILD treaters or XX% than starting with X Depth Tyvaso. PAH nicely disease to patients of prescribers true prescribers, patients XX% begin refer treat these is the we're the which or to more see prescribers means along within

particularly force ILD us sales into lean physicians, setting. recent community to will the Our the expansion to continue in allow

to -- been While tremendous our growth launched nebulized of Tyvaso we a in has tremendous continue last has DPI we value a portfolio. of since been it the source Tyvaso year, appreciate

its Some the because patients to physicians reimbursement and continue reasons. for prefer nebulizer profile of or

Tyvaso patients X PH-ILD compared titrate In breath switching breadth the equivalent to that addition, DPI. titration of nebulizer pulmonologists we're increments in to aware before their This Tyvaso allows prefer DPI. using start X precise to increments some the and more

over DPI become products strategy the competitive platform reach should other advantage to this they a expect We market. potential

Q&A, a and I potential the reiterate to Before some have we current potential around near centered our Questions the competition received primarily commercial term address a we're take growth want inhaled around in our that we've with for confidence move to moment competitor. questions and well to treprostinil sotatercept portfolio. positioned

be source First, approved, on based X agents the It's sotatercept. will therapies. PAH to And replacement, not In will that PAH, PH-ILD a next with of drug important growth to the most note data appears our near-term the will indicated addition, where year, not nice it our of expected not recent factor entering existing be it armamentarium. with and approved the indicated therefore, for remain new will clinical respect and if Group in But extremely the therefore, to be if and in be it be this growth. our a will business. an we confident a space, for experience addition durability PAH it

considered pathways that cancers, conditions therapy of some viral current PAH. from result multiple other is care Targeting pathways of This infections. standard the serious like and multiple mirrors for pathogenesis for failure heart pathogenic

including sotatercept our prostacyclins studied PAH treprostinil XX% combination other products, analogs, only patients In concomitant was on fact, or products. with in prostacyclin including of

the a longer. us of the sotatercept patients, We pathway revenue phenomenal of allows And patients if easily, patients to relatively because our on the DPI already Tyvaso medicines cover those on convenience speaking, benefits a the that's course, live addition prostacyclin. helps will longer, prostacyclin believe not of be likewise, and for for standpoint physicians from patients

DPI other the now to with believe demonstration in has preferred reach to and clear Tyvaso could patient satisfaction a of the demonstrated physician X,XXX patient and Tyvaso we inhaled been DPI. format. have our DPI XX% Moving treprostinil product a the more that than pre-study market. interest patients, prescribed We

Tyvaso deep DPI load breathing in device. patients low-flow X profile the consistently just per can when lungs and tidal its Tyvaso because a treprostinil inhaler of breath required also Tyvaso into times the with actual the requires a On position and and is X patients day. inhalation competitor facilitates that hold differentiated from actuate to only potential DPI its delivery the easy-to-use cleaning simple, inhale with cartridge DPI's generally that, of only device inhaler an top dose. using no open

early proud up, be we our So in appreciated quarter, business PAH to and wrap we're this we extremely prescribers with growth the commercial of our record we're will inroads to prescribers make in for base current PH-ILD by performance of continue as and sustainable alike. and stages our think patients to continue portfolio

it back So for I'll turn with that, over Martine, Q&A. you to the

Martine Rothblatt

coupled investment let's efforts lung for our session. with the disease, with the can tell manufacturing novel Operator, Therapeutics rare Mike. truly compelling supporting start cash-generating potential commercial business programs. Q&A Thanks, R&D organ everyone I hope a a that in is United strong revolutionary

Operator

question Stanley. Terence [Operator comes Morgan from first Instructions] with Flynn Today's

Terence Flynn

include Congrats Mike, Great. driven? quarter adds then offer maybe was shook you I was quarter, Tyvaso did And us in been if Thank the that levels all just patient the Like tell where wondering, for on this progress. quarter? it's you a Tyvaso if the for was that's -- on net can pretty level. on Or a inventory any build? out are specifically. to able XXX demand at consistent perspective all significant you, question the

Martine Rothblatt

Mike? Terence. you, Thank

Michael Benkowitz

Yes. Sure.

sometimes per of the quarter. little kind in roughly sometimes at XXX, higher, kind clip adds lower, range continue of a little that So that but a along net of to kind

happy of third in that really I we're continued a record the we said And and with progress. as quarter, So saw that, number prescriptions starts.

on And kind therapy. pull that continue patients of so and through to just keep those

So is the reflect revenue revenue infer that I on and from we're think the inventory numbers revenues with pleased -- numbers not front. From underlying demand. standpoint progress can number the numbers, the patient revenue an you what that --

seen So well forward. inventory since with MannKind inventory plus we significant that said, next build really positioned year, And we're at we've think the the June, there quarter. I enhancements going wasn't from a an what's in really as coming we're, standpoint

Martine Rothblatt

Operator, question Thank you next Mike. much, please? very

Operator

Absolutely.

next Our Oppenheimer. from with comes question Singh Hartaj

Hartaj Singh

for you quarter. the nice really question, and Thank Great.

has Just different revenues of nice but maybe really your which had a you OpEx that across that a board, to little talked previously. tack, bit pretty especially and algorithm Tyvaso, really firm holding is James the that staying about you're

getting more franchise PAH keep to as keep better. progression? just seems you even just talk becomes to margin that better expect a you operating profitable? And your on getting little Can about bit do Your that

Martine Rothblatt

Thank is Financial you very Officer. Chief James Edgemond much, Hartaj. our

you question? that could answer James, please So

James Edgemond

Thanks, the Martine. question. Thank Yes. you for

and will no we more prior reminder, exceeds on we question, your alluded apply will operating and budgets to for that you year cash in that a As where still in XXXX, of algorithm revenue. spend budget this example, XX%

So continuing to our this algorithm forward, and apply. budget we year expect

we With enrollment budgets be spends those which around could respect by on continued bounce typically at the and have remember, that, for in operating can an basis. But our you And timing we've look the operating example. time. an your improving revenue our specifically, growth, demonstrated, expenses because of quarter-to-quarter around over budget environment margin, to question annual trial and will that clinical impacted margins on

well. as of when of successful heard, kind algorithm, from budget But about in do the the Michael, Michael good will investments of And some about responsibility you talk expenses. expect to to want apply growing revenue the to a stewards we very think continue perspective, quarter has and fiduciary you and fiduciary as be we continue and made financial a that

very thank you to much. back So And you. Martine,

Martine Rothblatt

you, next Thank please. Operator, James. question you, Hartaj. Thank

Operator

TD question from with comes Cowen. Thome Our next Joseph

Joseph Thome

quarter. of business think Or transplant? How as in organ do kidney kidney should we goal the populations kidney, about products? these sort are you of Obviously, Miro and that? X view on largely shots the of the side think that implant, could this progress the discrete from Xeno kidney Iviva lot each the When these benefit of we a on of there

Martine Rothblatt

you, Thank Joe.

diversity of disease is a the all specifically on to answer kidney there types within positively, the of above, end-stage think the are goal. I of different shots there of organ both large and Definitely, But is multiple generally above specific. manifestation be disease. of

Autologous cells. a it's populations. groups, different So I of could allogeneically one disease to cellularized going kidney Miro the much primary a see end-stage or kidney from with very products kidney whether kidney, Xeno or other Iviva patient

As you know, people million just States are X.X there on dialysis. Joe, the than more in United

the other level our of really patient populations question, use. So demand kidney off please. is of we're each physicians organ find their charts, very, next these the confident for the technologies we'll and for Joe. Operator, question receptive and very Thanks technologies and that

Operator

Absolutely.

Our comes next Yang from Jefferies. question Eun with

Eun Yang

wondering just So you TETON the fibrosis. PH-ILD? study you you for are not pulmonary bridging a recently it's another Phase I'm you similar in need to nebulizer the using why study to the And DPI trial. not think started DPI progressive formulation do once from III may approved,

Martine Rothblatt

the question. she trial Dr. Very responsible executive Peterson, I'd like clinical to answer good question. your ask if for Leigh that please could study,

Leigh Peterson

for the Thanks sure. Yes, question.

between as Regarding as to the DPI. not many use the why We using possible nebulizer to want we're remove the studies. variables

that these will study And with DPI seek studies a once having X, yes, same those. required TETON between for what for determine results approval. -- with we we're So delivery sticking INCREASE device approval TETON It's we'll the TETON definitely conversations FDA nebulizer. X see of and PPF, be the so to for the ongoing and still we're with the

Martine Rothblatt

you Eun, Thank please. Operator, your you much, Peterson. Thank very question. question very for next Dr. much,

Operator

comes today JPMorgan. Fye question with from next Our Jessica

Jessica Fye

Tyvaso. on Question

mix the mentioned, the Tyvaso starts Can among Tyvaso Tyvaso you So of and franchise? talk DPI. mix new what who you're for the which between new nebulized on recognizing end the as nebulized that DPI DPI as might you titration suggest about within starts the seeing the well latest and as mix expectations up your understates proportion that could longer-term of dynamic longer-term

Martine Rothblatt

much, very give please? question, Mike, some able would that to you Thank be you on Jess. color

Michael Benkowitz

Sure. Happy to.

with the -- to DPI. mix respect Jess, the nebulizer and So, with between to respect sorry, the

in couple it's in third X/X think the we in That true. to we hold quarters That's the the of that XX% but was quarter X/X, kind XX% third of that what said kind actually to the of XX% to saw nebulizer. on I DPI. of DPI, in X/X than That kind quarters, higher couple XX% of a points it's the neighborhood prior the for nebulizer last been nebulizer. continues generally quarter. of

to Part goes a going in Medicare it's D could first that stay towards and redesign the expect under the down. some of bit year kick little of after the of tip elements kind DPI when out-of-pocket new It there. I the IRA patient up

DPI. there's I to that So continue reimbursement nebulizer, reason nebulizer. little opening using or But -- tilt challenges said in to -- as the to a more my for going comments, opening things might think extent I the be my for do a that I that role bit towards a

some we've I think different, that versa. one what is over that and device to years vice in delivery learned we XX XX over and to patients this better very are the have been another react space

So is really to device patients of have either United of it from that multiple patients. agnostic offer day, benefiting -- we're to the kind the because, way, we which really the Therapeutics as at just we're happy And are we're end the product. options

Martine Rothblatt

question. please. thank you one of question. the for Jess, And the last call, have Thank much, at just for you We're end Mike. but we last time so the question, Operator,

Operator

with Our today UBS. comes question Verma Ash from final

Ashwani Verma

my Thanks the quarter. on Congrats for taking question.

I X. So have

be fulfill enabled expansion would is production MannKind DPI, first. line that level On the the building? Is fully for to second minimum MannKind, now you X.Xx levels at by distributors? Or June. in That's contractual that your for of supply up manufacturing the the partner, Tyvaso was that only at your allowing that

the just other in if that pipeline studies time curious there excited mean is primarily just any that. I But playing the for the about because heterogeneity disease? PPF, of factor Tyvaso, of And very these enrolling for curious, lot there's Or IPF. protracted. a bit Is of lines are a little

Martine Rothblatt

for that that thanks question Ash, compound or question. Okay,

question, the your question to the of Poisson. done answered of let's that Vice for fibrosis first? Pat part Leigh by you go study, have pulmonary answering will question to Dr. the first in your time second Executive enrollment Peterson. President So be one Operations, can relating answered the by part our first Technical your he's lines of the when relating manufacturing be Pat, for part And

Patrick Poisson

Sure. Thanks, Martine, question. and thanks the for

earlier growth So improvements online implemented year term, first and XXXX. Tyvaso fulfill both in DPI. see midterm we'll is the as certainly process that the of demand will half ILD, we coming we this Longer near or need the equipment new in

as online. and able fulfill inventory do so right SPs So to And new at then for well able until levels of comes to be now, be the prepared the we're demand [ maintain we'll we'll And future. ]. equipment the

Martine Rothblatt

Pat. Peterson? Thank Dr. you,

Leigh Peterson

Yes.

we're But on time TETON finish line actually for -- the the of right, on at question we So in TETON you're targeting enrollment patients sample enrollment have We the increased we're our XXXX. studies XXX size. the still the our study. I program. thanks mean end the each haven't of now And of increased target to

which is, you're saw. of that fairly additional to is increased us to success. There overall size those And we because sample mentioned deviations what the of blinded some haven't the rapid, right, and line increase these the prompted to is caution studies, basically data patients. to enroll do pace variability for completers, the the And of But just of you reason the chance again, time looks, and of enrollment of out was increase exactly our the we the into routine just we FVC disease. standard that

Martine Rothblatt

much, so Thank Dr. you Peterson.

so thank the Ash, you much question. for

great In conclusion, be Therapeutics. here United as mentioned earlier, in to a we're such at happy really position

continued solid strong a results commercial ahead. business, We posting with have record growth

that pipeline therapies to largest a critical address our of of needs. of the unmet one medical by could the novel a decade. end again double have the plan long-term have we We revenue And

of our shareholders above All patients, succeed. while the helping and employees

may call. terminate the now you Operator,

Operator

visiting week United of will Thank Therapeutics Earnings for for you by Webcast. and in Presentations the United webcast Corporation at replay of be available Relations for A Investor X this the participating section Events today's website Therapeutics rebroadcast ir.unither.com.

disconnect lines, now a wonderful day. your may have You and

United Therapeutics (UTHR) 1 Nov 232023 Q3 Earnings call transcript